Cargando…

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

BACKGROUND: Several oncogenic drivers in non-small cell lung cancer (NSCLC) are considered actionable with available or promising targeted therapies. Although targetable drivers rarely overlap with each other, there were a minority of patients harboring co-occurring actionable oncogenic targets, who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yiming, Wang, Shuyuan, Yang, Zhengyu, Dong, Yu, Wang, Yanan, Zhang, Lele, Hu, Hai, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242190/ https://www.ncbi.nlm.nih.gov/pubmed/34221980 http://dx.doi.org/10.3389/fonc.2021.665484

Ejemplares similares

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Qian, Jie, et al.
Publicado: (2021)

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung
por: Wang, Yanan, et al.
Publicado: (2021)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors
por: Zhang, Runjiao, et al.
Publicado: (2021)

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
por: Yuan, Bo, et al.
Publicado: (2020)

Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma
por: Xu, Jian-Zhao, et al.
Publicado: (2021)

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line
por: Lu, Jun, et al.
Publicado: (2019)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

The Oncogene IARS2 Promotes Non-small Cell Lung Cancer Tumorigenesis by Activating the AKT/MTOR Pathway
por: Di, Xin, et al.
Publicado: (2019)

Local consolidative therapy for synchronous oligometastatic non‐small cell lung cancer treated with first‐line pembrolizumab: A retrospective observational study
por: Chen, Ya, et al.
Publicado: (2022)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

Hidden among the crowd: differential DNA methylation-expression correlations in cancer occur at important oncogenic pathways
por: Mosquera Orgueira, Adrián
Publicado: (2015)

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
por: Jiang, Liyan, et al.
Publicado: (2017)

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
por: Remon, J., et al.
Publicado: (2018)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
por: Guo, Wenhui, et al.
Publicado: (2021)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Circular RNA circ_0010235 sponges miR-338-3p to play oncogenic role in proliferation, migration and invasion of non-small-cell lung cancer cells through modulating KIF2A
por: Zhu, Yanan, et al.
Publicado: (2021)

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
por: Schubert, Laura, et al.
Publicado: (2023)

Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma
por: Dong, Yu, et al.
Publicado: (2017)

The Oncogenic Potential of Human Cytomegalovirus and Breast Cancer
por: Herbein, Georges, et al.
Publicado: (2014)

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
por: König, David, et al.
Publicado: (2021)

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer
por: Daoud, Alia, et al.
Publicado: (2017)

Discovery of co-occurring driver pathways in cancer
por: Zhang, Junhua, et al.
Publicado: (2014)

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
por: Wang, Rui, et al.
Publicado: (2015)

Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer
por: Yu, Lian, et al.
Publicado: (2021)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius, Barbara, et al.
Publicado: (2016)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy
por: Sun, Shengjie, et al.
Publicado: (2021)

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022)

Evaluation of the Oncogene Function of GOLPH3 and Correlated Regulatory Network in Lung Adenocarcinoma
por: Zhang, Tong, et al.
Publicado: (2021)

CT Appearance Pattern After Stereotactic Body Radiation Therapy Predicts Outcomes in Early-Stage Non-Small-Cell Lung Cancer
por: Yang, Yan, et al.
Publicado: (2021)

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
por: Kim, So Yeon, et al.
Publicado: (2020)

Integrative Multi-Omics Analysis of Identified NUF2 as a Candidate Oncogene Correlates With Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer
por: Chen, Mengqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sm2tbbt269gbmsk0e253t9k4fk